Company intelligence / Profile preview

Acarpia Farmaceutici

Milan, Lombardy, Italy

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Acarpia Farmaceutici develops and commercializes established, well-known small molecule drugs (e.g., colchicine, acetylsalicylic acid combinations, troxerutin/carbazochrome, alizapride hydrochloride) targeting cardiovascular, rheumatology, and other therapeutic areas, primarily through product repositioning and value enhancement. The company recently expanded access to its products in the Caribbean (CARICOM) and Mexico through a strategic partnership.

Therapeutic areas: ImmunologyRheumatologyInfectious DiseasesGastroenterologyHematologyCardiovascularOtherNeurologyWomen's Health
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

Fleboside

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

EarlyHealth Group

Beyond the preview

Go deeper on Acarpia Farmaceutici.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acarpia Farmaceutici.

Explore the full profile